Meta‑analysis of the efficacy and safety of sintilimab for treating advanced non‑small cell lung cancer

Xie,Jiejie; Wu,Xueyan; Wu,Jianmei; Huang,Fang; Xu,Luning

doi:10.3892/ol.2022.13545

Meta‑analysis of the efficacy and safety of sintilimab for treating advanced non‑small cell lung cancer

Authors:
- Jiejie Xie
- Xueyan Wu
- Jianmei Wu
- Fang Huang
- Luning Xu
View Affiliations

Affiliations: Department of Clinical Pharmacy, Sanming First Hospital, Affiliated Hospital of Fujian Medical University, Sanming, Fujian 353000, P.R. China
Published online on: October 12, 2022 https://doi.org/10.3892/ol.2022.13545
Article Number: 425
Copyright : © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the leading cause of death from malignant tumors in China, and non‑small cell lung cancer (NSCLC) accounts for >80% of all types of lung cancer. Novel immunotherapeutic agents targeting programmed death protein‑1 (PD‑1) and its ligands [programmed death ligands (PD‑L)1 and 2] have emerged as important therapeutic measures and trends in the treatment of advanced NSCLC. Sintilimab (trade name, Daboshu) is a humanized IgG4 monoclonal antibody targeting PD‑1 that was developed by Innovent Biologics and Eli Lilly and Company. Studies have shown that sintilimab has the characteristics of high affinity, long‑lasting stability and an increased target occupancy rate, and that it is a broad‑spectrum drug. The present study uses a meta‑analysis to evaluate the safety and efficacy of sintilimab in treating advanced NSCLC. The PubMed, Cochrane Library, Embase, Chinese Biomedical Literature, China National Knowledge Infrastructure, VIP Chinese Science and Technology Journal and Wanfang Medical databases were searched from their establishment until October 2021. Randomized controlled trials of patients with NSCLC who were treated with conventional chemotherapy (chemotherapy) plus sintilimab treatment or sintilimab alone, compared with a chemotherapy group, were included, and a meta‑analysis was performed using RevMan 5.3 software. The findings revealed that there was no significant difference between the conventional chemotherapy group and the sintilimab group in terms of the overall incidence of adverse drug reactions (ADR) or grade 3‑5 ADRs (risk ratio, 1.04; 95% confidence interval, 0.96‑1.14; P=0.33), respectively. Sintilimab coupled with chemotherapy outperformed standard chemotherapy in treating advanced NSCLC. The ADRs did not differ considerably from those of conventional chemotherapy, which will help in the assessment of the clinical efficacy of sintilimab combined with chemotherapy and conventional chemotherapy in treating advanced NSCLC.

View Figures

View References

1	Lan L, Zhao F, Cai Y, Wu RX and Meng Q: Analysis of epidemiological characteristics of malignant tumor mortality among Chinese residents in 2015. Zhonghua Liu Xing Bing Xue Za Zhi. 39:32–34. 2018.(In Chinese). PubMed/NCBI
2	Chen WQ: Cancer statistics: Updated cancer burden in China. Chin J Cancer Res. 27:12015. View Article : Google Scholar : PubMed/NCBI
3	Zhi XY, Zou XN, Hu M, Jiang Y, Jia MM and Yang GH: Increased lung cancer mortality rates in the Chinese population from 1973–1975 to 2004–2005: An adverse health effect from exposure to smoking. Cancer. 121:3107–3112. 2015. View Article : Google Scholar : PubMed/NCBI
4	Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R and Zhao J: Anlotinib: A novel multitargeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 11:1202018. View Article : Google Scholar : PubMed/NCBI
5	Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, et al: Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): An open-label, randomised phase 3 trial. Lancet. 390:29–39. 2017. View Article : Google Scholar : PubMed/NCBI
6	Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et al: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 376:629–640. 2017. View Article : Google Scholar : PubMed/NCBI
7	Kong J, Yang X, Kong H, Yang MX and Xie WP: Analysis of EGFR and ALK driving genes in 2394 patients with lung adenocarcinoma. J Nanjing Med Univ (Natural Science). 40:675–680. 2020.(In Chinese).
8	Qiao XL, Ai D, Liang H, Mu D and Guo Q: Analysis of gene expression and clinical characteristics of molecular targeted therapy for non-small cell lung cancer in Shandong. Zhongguo Fei Ai Za Zhi. 20:14–20. 2017.(In Chinese). PubMed/NCBI
9	Dermani FK, Samadi P, Rahmani G, Kohlan AK and Najafi R: PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol. 234:1313–1325. 2019. View Article : Google Scholar : PubMed/NCBI
10	Leprieur EG, Dumenil C, Julie C, Giraud V, Dumoulin J, Labrune S and Chinet T: Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer. 78:16–23. 2017. View Article : Google Scholar : PubMed/NCBI
11	Sheng Z, Zhu X, Sun Y and Zhang Y: The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. Oncotarget. 8:57826–5735. 2017. View Article : Google Scholar : PubMed/NCBI
12	Innovent Biologics: China's NMPA approves Innovent's antipd-l antibody Tyvyt^® (sintilimab injection) for Hodgkins lymphoma [media release]. Innovent Biologics (Suzhou) Co., Ltd.; Suzhou: 2018, http://innoventbio.com/en/#/news/123December 26–2018
13	Innovent Biologics, . Tyvyt^®(sintilimab): Chinese prescribing information. Innovent Biologics (Suzhou) Co., Ltd.; Suzhou: 2019
14	Wang J, Fei K, Jing H, Wu Z, Wu W, Zhou S, Ni H, Chen B, Xiong Y, Liu Y, et al: Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 11:1443–1451. 2019. View Article : Google Scholar : PubMed/NCBI
15	Zhang L, Qian Y, Li J, Cui C, Chen L, Qu S and Lu S: Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer. Future Oncol. 18:1896–1905. 2022. View Article : Google Scholar : PubMed/NCBI
16	Ye Z, Yang W, Xuan B, Li X, He J, Si H and Ma W: Efficacy and safety evaluation of sintilimab for cancer treatment: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 13:8951872022. View Article : Google Scholar : PubMed/NCBI
17	National Cancer Institute, . Common Terminology Criteria for Adverse Events (CTCAE) v4.0. NIH; Bethesda, MD: 2009
18	Cumpston MS, McKenzie JE, Welch VA and Brennan SE: Strengthening systematic reviews in public health: Guidance in the cochrane handbook for systematic reviews of interventions. (2nd edition). J Public Health (Oxf). 28:fdac0362022. View Article : Google Scholar
19	Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, et al: Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 15:1636–1646. 2020. View Article : Google Scholar : PubMed/NCBI
20	Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, Zhang L, Huang D, Cang S, Yang Z, et al: Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol. 16:1501–1511. 2021. View Article : Google Scholar : PubMed/NCBI
21	Liang X and Wei Z: Effect of sintilimab combined with chemotherapy on tumor markers and immune function of advanced non-small-cell lung cancer. Pak J Med Sci. 37:1063–1068. 2021. View Article : Google Scholar : PubMed/NCBI
22	He SY, Zhang M, Xu Z, Lu XL, Chen ZP and Zuo Y: Efficacy of sintilimab combined with chemotherapy in the treatment of non-small cell lung cancer and its effect on immune function. Chin Pract Med. 16:12–15. 2021.(In Chinese).
23	Hu XM, Li GY and Wang L: Clinical study of gemcitabine combined with Sintilimab in the treatment of stage IV lung squamous cell carcinoma. Chin J Clin Oncol Rehabilitation. 28:302–305. 2021.(In Chinese).
24	Chen Y, Liu W, Liang YH, Chen HF and Dong ZH: Observation on the efficacy of Sintilimab combined with amlotinib in the treatment of advanced non-small cell lung cancer. J Guangdong Medical University. 39:615–618. 2021.
25	Ai C, Ji SS, Tang L, Wang L, Yan X and Zhou MZ: Progress in antitumor clinical research of PD-1/PD-L1 inhibitors. Clin Med J. 19:62021.
26	National Comprehensive Cancer Network (NCCN), . NCCN Clinical Practice Guidelines in Oncology: Non-small cell lung cancer (version 1). NCCN; Plymouth Meeting, PA: 2021, https://www.nccn.org/professionals/physician_gls/
27	Guidelines Working Committee of the Chinese Society of Clinical Oncology, Chinese Society of Clinical Oncology (CSCO), . Chinese Society of Clinical Oncology (CSCO): Guidelines for the diagnosis and treatment of non-small cell lung cancer 2020. People's Health Publishing House; Beijing, China: pp. 42021
28	Cai JX, Siying Chen SY, Jianping Qin JP, Yue Zhang Y, Ruifeng Qi RF and Ye YM: Analysis of the efficacy and safety of Sintilimab in the treatment of patients with advanced colorectal cancer. Chin J Pharmacovigilance. 19:164–168. 2022.(In Chinese).
29	Zhang L, Mai WQ, Jiang WY and Geng Q: Sintilimab: A promising antitumor PD-1 antibody. Front Oncol. 10:5945582020. View Article : Google Scholar : PubMed/NCBI
30	Zhu D, Li YY, Song YQ and Li YJ: Clinical research progress of PD-1 inhibitor Sintilimab. Chinese J Hospital Pharmacy. 40:120–123. 2020.
31	Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Aguilera JV, Chintakuntlawar A, et al: Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol. 5:1008–1019. 2019. View Article : Google Scholar : PubMed/NCBI
32	Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, Kähler KC, Loquai C, Reinmuth N, Steins M, et al: Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 45:7–18. 2016. View Article : Google Scholar : PubMed/NCBI